Under Jorgensen's leadership, Novo Nordisk became a world leader in the weight-loss drug market, with sky-rocketing sales of its Wegovy and Ozempic treatments which propelled its share price to ...

So, the semaglutide ... why I continue to cover Novo Nordisk with a "Strong Buy" rating despite the increased competition from Eli Lilly and Trump's attempts to lower drug prices.

Novo Nordisk (NYSE: NVO) stock jumped 3% through 10:55 a.m. Tuesday on some potentially positive news in the GLP-1 weight loss market. As Reuters reports today, an online weight loss company ...

FRANKFURT, Germany (AP) — Danish pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy ... on the same basic ingredient, semaglutide. A runaway pet zebra has ...

Novo Nordisk’s semaglutide drug is in a class of drugs known as GLP-1 agonists, which simulate a hormone that would naturally be released during digestion. Its drug, marketed as Ozempic ...

Novo Nordisk is banking on fresh leadership ... closer to entering the market. Unlike oral semaglutide, Eli Lilly's pill is a small-molecule drug and not a peptide medication.

With a U.S. Food and Drug Administration ban on copycat semaglutide drugs now in effect, Novo Nordisk is launching a series of initiatives to improve access to authentic versions of its ...